# Durvalumab and Tremelimumab in Resectable HCC

> **NCT05440864** · PHASE2 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 28 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT05440864
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-26
- **Primary completion:** 2025-11
- **Final completion:** 2026-11
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2024-10-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05440864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05440864, "Durvalumab and Tremelimumab in Resectable HCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05440864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*